407
Participants
Start Date
November 27, 2018
Primary Completion Date
June 23, 2024
Study Completion Date
February 26, 2027
Durvalumab
Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] until clinical progression/ deterioration or confirmed radiological progression.
Placebo
Matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression
Research Site, Taipei
Research Site, Taipei
Research Site, Taoyuan District
Research Site, Quezon City
Research Site, Quezon City
Research Site, México
Research Site, San Juan City
Research Site, Baguio City
Research Site, Cebu
Research Site, Bacolod
Research Site, Davao City
Research Site, Cagayan de Oro
Research Site, Taipei
Research Site, Taipei
Research Site, Mexico City
Research Site, Edirne
Research Site, Istanbul
Research Site, Taichung
Research Site, Daegu
Research Site, Konya
Research Site, Malatya
Research Site, Gwangju
Research Site, Monterrey
Research Site, Tainan City
Research Site, San Luis Potosí City
Research Site, Culiacán
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Shenyang
Research Site, Moscow
Research Site, Moscow
Research Site, Changchun
Research Site, Harbin
Research Site, Murmansk
Research Site, Saint Petersburg
Research Site, Shanghai
Research Site, Shanghai
Research Site, Shanghai
Research Site, Nanjing
Research Site, Yangzhou
Research Site, Bengbu
Research Site, Obninsk
Research Site, Qingdao
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Ningbo
Research Site, Linhai
Research Site, Wenzhou
Research Site, Fuzhou
Research Site, Karamsad
Research Site, Vadodara
Research Site, Chongqing
Research Site, Volgograd
Research Site, Changsha
Research Site, Kazan, Tatarstan
Research Site, Nashik
Research Site, Saransk
Research Site, Wuhan
Research Site, Samara
Research Site, Zhengzhou
Research Site, Zhengzhou
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Nanning
Research Site, Bangalore
Research Site, Bengaluru
Research Site, Kirov
Research Site, Chengdu
Research Site, Chengdu
Research Site, Chengdu
Research Site, Novosibirsk
Research Site, Novosibirsk
Research Site, Kolkata
Research Site, Ürümqi
Research Site, Hong Kong
Research Site, Mexico City
Research Site, Bialystok
Research Site, Gdansk
Research Site, Poznan
Research Site, Tomaszów Mazowiecki
Research Site, Warsaw
Research Site, Seoul
Research Site, Adana
Research Site, Ankara
Lead Sponsor
AstraZeneca
INDUSTRY